

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

### SECTION 1: IDENTIFICATION

Product name : Oxfendazole / Oxclozanide Formulation

#### Manufacturer or supplier's details

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street  
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure : Category 2 (Liver, Testis, Brain)

#### GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

---

Version 5.0	Revision Date: 14.04.2025	SDS Number: 7942502-00009	Date of last issue: 06.04.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

---

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

---

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
oxclozanide	2277-92-1	>= 30 -< 60
oxfendazole	53716-50-0	>= 10 -< 30
Starch, oxidized	65996-62-5	>= 10 -< 30
Magnesium stearate	557-04-0	< 10

---

## SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.

Remove contaminated clothing and shoes.

Get medical attention.

Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May damage fertility. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

---

## SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO <sub>x</sub> ) Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Hazchem Code	: 2Z

---

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protection	: Use personal protective equipment.
----------------------------------	--------------------------------------

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0	Revision Date: 14.04.2025	SDS Number: 7942502-00009	Date of last issue: 06.04.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

tive equipment and emergency procedures	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	<ul style="list-style-type: none"><li>: Avoid release to the environment.</li><li>Prevent further leakage or spillage if safe to do so.</li><li>Retain and dispose of contaminated wash water.</li><li>Local authorities should be advised if significant spillages cannot be contained.</li></ul>
Methods and materials for containment and cleaning up	<ul style="list-style-type: none"><li>: Sweep up or vacuum up spillage and collect in suitable container for disposal.</li><li>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).</li><li>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.</li><li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li><li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li></ul>

## SECTION 7. HANDLING AND STORAGE

Technical measures	<ul style="list-style-type: none"><li>: Static electricity may accumulate and ignite suspended dust causing an explosion.</li><li>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.</li></ul>
Local/Total ventilation	<ul style="list-style-type: none"><li>: If sufficient ventilation is unavailable, use with local exhaust ventilation.</li></ul>
Advice on safe handling	<ul style="list-style-type: none"><li>: Do not get on skin or clothing.</li><li>Do not breathe dust.</li><li>Do not swallow.</li><li>Avoid contact with eyes.</li><li>Wash skin thoroughly after handling.</li><li>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment</li><li>Keep container tightly closed.</li><li>Minimize dust generation and accumulation.</li><li>Keep container closed when not in use.</li><li>Keep away from heat and sources of ignition.</li><li>Take precautionary measures against static discharges.</li><li>Do not eat, drink or smoke when using this product.</li><li>Take care to prevent spills, waste and minimize release to the environment.</li></ul>
Hygiene measures	<ul style="list-style-type: none"><li>: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.</li><li>When using do not eat, drink or smoke.</li></ul>

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0	Revision Date: 14.04.2025	SDS Number: 7942502-00009	Date of last issue: 06.04.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
oxclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Starch, oxidized	65996-62-5	TWA (inhal- able dust)	0.5 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	AU OEL
		TWA (Inhal- able particu- late matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Res- pirable par- ticulate mat- ter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

Material	: Chemical-resistant gloves
Remarks Eye protection	: Consider double gloving. : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: powder
Colour	: white to off-white, light cream, cream
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: Not applicable
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable
Relative vapour density	: Not applicable
Relative density	: No data available

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

Density	: 0.88 g/cm <sup>3</sup>
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

---

## SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation Skin contact Ingestion Eye contact
-----------------	--

### Acute toxicity

Not classified based on available information.

### Components:

#### **oxclozanide:**

Acute oral toxicity	: LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
---------------------	--

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

**oxfendazole:**  
Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg  
LD50 (Dog): 1,600 mg/kg  
LD50 (sheep): 250 mg/kg

### **Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

### **Skin corrosion/irritation**

Not classified based on available information.

### **Components:**

#### **oxclozanide:**

Remarks : Not classified due to lack of data.

#### **oxfendazole:**

Species : Rabbit  
Result : No skin irritation

#### **Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Components:**

#### **oxclozanide:**

Remarks : Not classified due to lack of data.

#### **oxfendazole:**

Species : Rabbit

**Oxfendazole / Oxclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

Result : No eye irritation

**Magnesium stearate:**

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****oxyclozanide:**

Exposure routes	: Dermal
Remarks	: Not classified due to lack of data.

**Magnesium stearate:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****oxyclozanide:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
	Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative

## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
 Date of first issue: 19.03.2021

Test Type: unscheduled DNA synthesis assay  
 Species: Rat  
 Cell type: Liver cells  
 Application Route: Oral  
 Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
 Species: Mouse  
 Application Route: Oral  
 Result: positive

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
 Method: OECD Test Guideline 473  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### oxclozanide:

Remarks : Not classified due to lack of data.

#### oxfendazole:

Species : Rat  
 Application Route : Oral  
 Exposure time : 1 Years  
 Symptoms : No adverse effects  
 Target Organs : Liver

Species : Rat

**Oxfendazole / Oxclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

Application Route	:	Oral
Exposure time	:	2 Years
Symptoms	:	No adverse effects
Target Organs	:	Liver

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****oxyclozanide:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat, male and female Application Route: Oral General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development Result: No effects on fertility
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development Result: No effects on fertility
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity, No teratogenic effects, No effects on fertility
Effects on foetal development	: Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity, No teratogenic effects
	Test Type: Development Species: Rat Application Route: Oral

**Oxfendazole / Oxclozanide Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
7942502-00009Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

General Toxicity Maternal: LOAEL: 100 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 32 mg/kg body weight  
Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

**oxfendazole:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Fertility: NOAEL: 17 mg/kg body weight  
Target Organs: Testes  
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.9 mg/kg body weight  
Target Organs: Liver  
Result: No effects on fertility

Test Type: Fertility  
Species: Mouse  
Application Route: Oral  
Duration of Single Treatment: 1 Months  
Fertility: NOAEL: 750 mg/kg body weight  
Target Organs: Testes  
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: positive, Fetal effects

Test Type: Embryo-foetal development  
Species: Rat  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: positive, Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 108 mg/kg body weight  
Result: positive, Embryo-foetal toxicity, foetal abnormalities

Test Type: Embryo-foetal development

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version  
5.0

Revision Date:  
14.04.2025

SDS Number:  
7942502-00009

Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - Assessment

: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

### **Magnesium stearate:**

Effects on fertility

: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development

: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### **STOT - single exposure**

May cause damage to organs (Central nervous system) if swallowed.

### **Components:**

#### **oxclozanide:**

Exposure routes  
Target Organs  
Assessment

: Oral  
: Central nervous system  
: May cause damage to organs.

### **STOT - repeated exposure**

May cause damage to organs (Liver, Testis, Brain) through prolonged or repeated exposure.

### **Components:**

#### **oxclozanide:**

Target Organs  
Assessment

: Brain, Liver  
: May cause damage to organs through prolonged or repeated exposure.

#### **oxfendazole:**

Exposure routes  
Target Organs  
Assessment

: Oral  
: Liver, Testis  
: May cause damage to organs through prolonged or repeated exposure.

**Oxfendazole / Oxclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

**Repeated dose toxicity****Components:****oxclozanide:**

Species	:	Rat
NOAEL	:	9 mg/kg
LOAEL	:	44.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver, spleen, Adrenal gland
Symptoms	:	Liver effects
Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

**oxfendazole:**

Species	:	Rat
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Blood, Liver, Testis
Species	:	Rat
NOAEL	:	3.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver, Testis
Species	:	Mouse
NOAEL	:	750 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Target Organs	:	Liver
Species	:	Mouse
NOAEL	:	37.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver
Species	:	Dog
NOAEL	:	6 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Remarks	:	No significant adverse effects were reported

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

Species	:	Dog
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Lymph nodes, thymus gland

Species	:	Dog
NOAEL	:	13.5 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Liver

### **Starch, oxidized:**

Species	:	Rat
NOAEL	:	22,500 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

### **Magnesium stearate:**

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

### **Aspiration toxicity**

Not classified based on available information.

### **Components:**

#### **oxyclozanide:**

||| Not applicable

### **Experience with human exposure**

### **Components:**

#### **oxyclozanide:**

Ingestion	:	Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression
-----------	---	--

---

## SECTION 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

### **Components:**

#### **oxyclozanide:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.69 mg/l Exposure time: 48 h
---	---	---

**Oxfendazole / Oxclozanide Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
7942502-00009Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

Method: OECD Test Guideline 202

**oxfendazole:**

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l  
Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.059 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.023 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h

**Oxfendazole / Oxclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****oxyclozanide:**

Stability in water : Hydrolysis: 50 %(156 d)  
Method: OECD Test Guideline 111

**oxfendazole:**

Stability in water : Hydrolysis: < 5 %(4 d)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3.99  
pH: 7  
Method: OECD Test Guideline 107

**oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****oxyclozanide:**

Distribution among environmental compartments : log Koc: 4.83  
Method: OECD Test Guideline 106

**oxfendazole:**

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

||| Distribution among environmental compartments : log Koc: 3.2

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxclozanide)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

#### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(oxfendazole, oxclozanide)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

#### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxclozanide)

Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 7942502-00009      Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### ADG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.  
(oxfendazole, oxclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
Hazchem Code : 2Z  
Environmentally hazardous : yes

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons Standard) Instrument : Schedule 6 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)  
Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

## SECTION 16: ANY OTHER RELEVANT INFORMATION

### Further information

Revision Date : 14.04.2025  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Oxfendazole / Oxclozanide Formulation**

---

Version 5.0	Revision Date: 14.04.2025	SDS Number: 7942502-00009	Date of last issue: 06.04.2024 Date of first issue: 19.03.2021
----------------	------------------------------	------------------------------	---

---

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyy

**Full text of other abbreviations**

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
AU OEL	: Australia. Workplace Exposure Standards for Airborne Contaminants.
ACGIH / TWA	: 8-hour, time-weighted average
AU OEL / TWA	: Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Oxfendazole / Oxclozanide Formulation

Version  
5.0

Revision Date:  
14.04.2025

SDS Number:  
7942502-00009

Date of last issue: 06.04.2024  
Date of first issue: 19.03.2021

---

AU / EN